EPIGENETIC SILENCING OF FBXW7 THROUGH PROMOTOR HYPERMETHYLATION IN OVARIAN CANCER

被引：0
|
作者：
Tamimi, Y. [1 ]
Al Hinai, M. [2 ]
Gupta, I. [3 ]
Lakhtakia, R. [4 ]
Al Kalbani, M. [5 ]
Okamoto, A. [6 ]
Al Moundhri, M. [7 ]
Burney, I. [7 ]
机构：
[1] SQU, Biochem, Muscat, Oman
[2] SQU, Muscat, Oman
[3] Qatar Univ, Doha, Qatar
[4] BenRashed Univ, Dubai, U Arab Emirates
[5] Sultan Qaboos Univ SQU Hosp SQUH, Gynecol, Muscat, Oman
[6] Jikei Univ, Dept Obstet & Gynecol, Tokyo, Japan
[7] SQUH, Med, Muscat, Oman
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2019年 / 29卷
关键词：
D O I：
10.1136/ijgc-2019-ESGO.1038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP994
引用
收藏
页码：A525 / A525
页数：1
相关论文
共 50 条
  • [1] EPIGENETIC SILENCING OF FBXW7 THROUGH PROMOTOR HYPERMETHYLATION IN OVARIAN CANCER
    Al Kalbani, M.
    Al Hinai, M.
    Gupta, I.
    Burney, I.
    Al Moundhri, M.
    Tamimi, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 625 - 625
  • [2] Epigenetic silencing of FBXW7 through promotor hypermethylation in ovarian cancer
    Tamimi, Y.
    Al Hinai, M.
    Gupta, I.
    Lakhtakia, R.
    Al Kalbani, M.
    Burney, I.
    Okamoto, A.
    Al Mounthri, M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 742 - 742
  • [3] FBxW7 as a predictor of outcomes in ovarian cancer
    Dickson, Elizabeth L.
    Vogel, Rachel
    Leung, Samuel
    Chow, Christine
    Huntsman, David
    Gilks, Blake
    Subramanian, Subbaya
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S72 - S73
  • [4] FBxW7 duality in ovarian cancer: Novel insight into ovarian cancer pathogenesis
    Dickson, Elizabeth Louise
    Li, Lihua
    Leung, Samuel
    Chow, Christine
    Vogel, Rachel Isaksson
    Huntsman, David
    Gilks, C. Blake
    Subramanian, Subbaya
    CLINICAL CANCER RESEARCH, 2013, 19
  • [5] FBXW7γ is a tumor-suppressive and prognosis-related FBXW7 transcript isoform in ovarian serous cystadenocarcinoma
    Xu, Zhou
    Zhuang, Lin
    Wang, Xiaoyin
    Li, Qianrong
    Sang, Yan
    Xu, Jiao
    FUTURE ONCOLOGY, 2020, 16 (25) : 1921 - 1930
  • [6] Promoter hypermethylation is not the major mechanism for inactivation of the FBXW7 β-form in human gliomas
    Gu, Zhaodi
    Inomata, Kenichi
    Mitsui, Hidetoshi
    Horii, Akira
    GENES & GENETIC SYSTEMS, 2008, 83 (04) : 347 - 352
  • [7] FBXW7 polymorphism asserts susceptibility to colorectal cancer
    Uroog, Laraib
    Zeya, Bushra
    Imtiyaz, Khalid
    Wani, Rauf Ahmad
    Rizvi, M. Moshahid Alam
    GENE, 2024, 901
  • [8] FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors
    Kitade, Shoko
    Onoyama, Ichiro
    Kobayashi, Hiroaki
    Yagi, Hiroshi
    Yoshida, Sachiko
    Kato, Masaya
    Tsunematsu, Ryosuke
    Asanoma, Kazuo
    Sonoda, Kenzo
    Wake, Norio
    Hata, Kenichiro
    Nakayama, Keiichi I.
    Kato, Kiyoko
    CANCER SCIENCE, 2016, 107 (10) : 1399 - 1405
  • [9] FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of β-catenin signaling
    Zhong, Liping
    Pan, Yuefen
    Shen, Junjun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
  • [10] Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
    Akhoondi, Shahab
    Lindstrom, Linda
    Widschwendter, Martin
    Corcoran, Martin
    Bergh, Jonas
    Spruck, Charles
    Grander, Dan
    Sangfelt, Olle
    BREAST CANCER RESEARCH, 2010, 12 (06):
12345